Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NGM282 in primary biliary cholangitis
NCT02135536Phase 2Completed
- Sponsor
- NGM Biopharmaceuticals
- Start
- May 2014
- Primary completion
- Feb 2016
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 3
01
Overview
A Phase 2 trial of aldafermin in primary biliary cholangitis (PBC), sponsored by NGM Biopharmaceuticals. Started May 2014; status: completed.
02
Drugs
aldafermin
03
Conditions
primary biliary cholangitis (PBC)
Beyond the preview
Go deeper on NCT02135536.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02135536.